Lack of association between expression of MRP2 and early relapse of colorectal cancer in patients receiving FOLFOX‑4 chemotherapy

Mirakhorli,Mojgan; Shayanfar,Nasrin; Rahman,Sabariah   Abdul; Rosli,Rozita; Abdullah,Syahrilnizam; Khoshzaban,Ahad

doi:10.3892/ol.2012.889

Lack of association between expression of MRP2 and early relapse of colorectal cancer in patients receiving FOLFOX‑4 chemotherapy

Authors:
- Mojgan Mirakhorli
- Nasrin Shayanfar
- Sabariah Abdul Rahman
- Rozita Rosli
- Syahrilnizam Abdullah
- Ahad Khoshzaban
View Affiliations

Affiliations: Pathology Department, Faculty of Medicine and Health Sciences, University Putra Malaysia, 43400 UPM Serdang, Malaysia, Pathology Department, Hazrate Rasoul Akram Hospital, Tehran University, Tehran, Iran, Cluster of Medical Laboratory Sciences, Faculty of Medicine, Universiti of Teknologi MARA, Selayang Campus, 68100, Batu Caves, Selangor, Malaysia, Medical Genetics Laboratory, Faculty of Medicine and Health Sciences, University Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia, Iranian Tissue Bank Research and Preparation Center, Imam Khomeini Hospital Complex, Tehran University of Medical Science, Tehran, Iran
Published online on: August 31, 2012 https://doi.org/10.3892/ol.2012.889
Pages: 893-897

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recurrence following failure of chemotherapy limits the application of high doses of anticancer drugs currently used for eliminating cancerous cells. It has been identified that ATP‑binding cassette (ABC) multidrug transporters are associated with chemoresistance, which is a major obstacle in cancer therapy. The present study aimed to investigate the association of pretherapeutic multidrug resistance‑associated protein 2 (MRP2) expression with response to chemotherapy in stage ӀӀ/ӀӀӀ colorectal cancer (CRC). Protein expression was determined by immunohistochemical analysis of 50 archival samples from patients who had not received preoperative chemotherapy and radiotherapy. All patients were treated with 5‑fluorouracil/leucovorin (FL) plus oxaliplatin (FOLFOX‑4) regimen for 6 months following curative resection. During the 12 months of follow‑up, local and distant recurrences were observed in 15 (30%) cases, of which 5 occurred at the time of chemotherapy. MRP2 expression was observed in 24 (48%) and 7 (14%) cases in the tumor tissues and matched normal tissues, respectively. A significant difference was observed between the positive expression frequency in the tumor tissues compared to the surrounding normal mucosa (P=0.003). The incidence of recurrence and metastasis for patients in the MRP2‑positive group was lower than that in the MRP2‑negative group (P>0.05); however, all 5 cases who demonstrated recurrence during their treatment were MRP2‑positive (P=0.022). MRP2 expression was not correlated with the clinicopathological markers in this group of patients. Kaplan‑Meier analysis revealed that MRP2 expression was not associated with a shorter disease‑free survival or overall survival of patients (P>0.05). The results of this study indicated that MRP2 is overexpressed in the course of CRC development and progression. However, expression of MRP2 was not associated with recurrence of patients treated with FL and oxaliplatin in the population studied.

View Figures

View References

1.	R MalekzadehF BishehsariM MahdaviniaR AnsariEpidemiology and molecular genetics of colorectal cancer in Iran: a reviewArch Iran Med12161169200919249887
2.	A SadjadiM NouraieMA MohagheghiA Mousavi-JarrahiR MalekzadehDM ParkinCancer occurrence in Iran in 2002: an international perspectiveAsian Pac J Cancer Prev6359363200516236000
3.	V CatalanoAM BaldelliP GiordaniS CascinuMolecular markers predictive of response to chemotherapy in gastrointestinal tumorsCrit Rev Oncol Hematol3893104200110.1016/S1040-8428(00)00114-111311657
4.	WT BeckCircumvention of multidrug resistance with anti-P-glycoprotein antibodies: clinical potential or experimental artifact?J Natl Cancer Inst877375199510.1093/jnci/87.2.73
5.	M TakanoR YumotoT MurakamiExpression and function of efflux drug transporters in the intestinePharmacol Ther109137161200610.1016/j.pharmthera.2005.06.00516209890
6.	GE SanduskyKS MintzeSE PrattAH DantzigExpression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarraysHistopathology416574200210.1046/j.1365-2559.2002.01403.x
7.	R KerbS HoffmeyerU BrinkmannABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2Pharmacogenomics25164200110.1517/14622416.2.1.5111258197
8.	R OhashiF TakahashiR CuiInteraction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cellCancer Lett252225234200710.1016/j.canlet.2006.12.02517276588
9.	K TaniguchiM WadaK KohnoA human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulationCancer Res56412441291996
10.	E BakosR EversE SinkóA VáradiP BorstB SarkadiInteractions of the human multidrug resistance proteins MRP1 and MRP2 with organic anionsMol Pharmacol57760768200010727523
11.	E CasadoJ De CastroC Belda-IniestaMolecular markers in colorectal cancer: genetic bases for a customised treatmentClin Transl Oncol9549554200710.1007/s12094-007-0102-817921101
12.	S GiacchettiB PerpointR ZidaniPhase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancerJ Clin Oncol181361472000
13.	WL AllenVM CoylePG JohnstonPredicting the outcome of chemotherapy for colorectal cancerCurr Opin Pharmacol6332336200610.1016/j.coph.2006.02.00516750422
14.	CA RabikME DolanMolecular mechanisms of resistance and toxicity associated with platinating agentsCancer Treat Rev33923200710.1016/j.ctrv.2006.09.00617084534
15.	K ZhangP MackKP WongGlutathione-related mechanisms in cellular resistance to anticancer drugsInt J Oncol1287188219989499449
16.	Y ItohM TamaiK YokogawaInvolvement of multidrug resistance-associated protein 2 in in vivo cisplatin resistance of rat hepatoma AH66 cellsAnticancer Res2216491653200212168849
17.	B LiedertV MaternaD SchadendorfJ ThomaleH LageOverexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatinJ Invest Dermatol121172176200310.1046/j.1523-1747.2003.12313.x12839578
18.	K ShenD CuiL SunM HanJ LiuInhibition of IGF-IR increases chemosensitivity in human colorectal cancer cells through MRP-2 promoter suppressionJ Cell BiochemJan242012(Epub ahead of print)
19.	LH SobinC WittekindInternational Union Against CancerTNM Classification of Malignant Tumors6th editionJohn Wiley & SonsNew Jersey2002
20.	HJ ArtsD KatsarosEG de VriesDrug resistance associated markers P-glycoprotein, multidrug resistance associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinomaClin Cancer Res5279828051999
21.	R UshijimaK TakayamaUM IzumiImmunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancerAnticancer Res2743514358200718214043
22.	T AndréC BoniL Mounedji-BoudiafOxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancerN Engl J Med350234323512004
23.	E HinoshitaT UchiumiK TaguchiIncreased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomasClin Cancer Res6240124072000
24.	P BorstR EversM KoolJ WijnholdsA family of drug transporters: the multidrug resistance-associated proteinsJ Natl Cancer Inst9212951302200010.1093/jnci/92.16.129510944550
25.	M YamasakiT MakinoT MasuzawaRole of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinomaBr J Cancer104707713201110.1038/sj.bjc.660607121206495
26.	GB Van den BroekM WildemanCR RaschMolecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiationInt J Cancer12426432650200919253368
27.	A MaciejczykE JagodaT WysockaR MatkowskiB GyörffyH LageP SurowiakABCC2 (MRP2, cMOAT) localized in the nuclear envelope of breast carcinoma cells correlates with poor clinical outcomePathol Oncol Res18331342201210.1007/s12253-011-9449-921986666